Abstract: The present invention relates to a method of treating vascular proliferation in a patient in need thereof. The method includes the step of administering a therapeutically effective amount of a type-1 somatostatin agonist to said patient.

Abstract: The use of stannylenes and germylenes of general formula (I) wherein: M represents a tin or geranium atom; L1 and L2 independently represent a group of formula: -E14(R14) (R?14) (R?14), -E15(R15) (R?15) or -E16(R16)) or together form a chain of formula -L?1-A- L?2; A represents a saturated or unsaturated chain comprising one, two or three elements of group 14; L?1 and L?2, represent, independently, a group of formula: -E14(R14) (R?14)-, E15(R15)- or -E16-; E14 is an element of group 14; E15 is an element of group 15; E16 is an element of group 16; R14, R?14, R?14, R15, R?15 and R16 represent variable groups as polymerization catalysts of heterocycles.

Abstract: A family of imidazole compounds useful for inhibiting the activity of prenyl transferases.

Abstract: The present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated Ginkgolide B (GKB), a component of the extract of Ginkgo biloba leaves in a method for decreasing the expression of peripheral-type benzodiazepine receptor (PBR) in cells of a patient in need thereof. Further, the present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated GKB in a method for decreasing the proliferation of cancer cells in a patient. More particularly, the present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated GKB in a method of decreasing cancer cell proliferation in a patient wherein the cancer cell is human breast cancer cell.

Abstract: A process for the preparation of an extract of Ginkgo biloba leaves, comprising i. extraction of the dried fragments of Ginkgo biloba leaves in ethanol containing a maximum of 20% by weight of water; ii. concentration of the extract under reduced pressure in the presence of an aqueous solution of sodium chloride and elimination of the dark oil from the remainder of the clear solution; iii. washing of the residual aqueous solution by liquid-liquid extraction with n-hexane, n-heptane or cyclohexane, iv. liquid-liquid extraction of the aqueous phase washed with ethyl acetate; and v. washing of the ethyl acetate phase obtained in stage iv with a sodium chloride solution followed by evaporation to dryness of the washed ethyl acetate phase and use of the resulting extract to treat cerebral and peripheral vascular disorders and neurodegenerative diseases.

Abstract: The invention concerns a product inhibiting transduction of G heterotrimeric protein signals combined with another anti-cancer agent, in particular farnesyltransferase inhibitors, taxol or gemcitabin, for simultaneous, separate or prolonged therapeutic use in cancer treatment.

Abstract: The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient. A pharmaceutical/cosmetic composition comprises the somatostatin or somatostatin agonist. Such products are used to prepare such compositions for the reduction of body weight in a human or mammalian animal.

Abstract: A method of treating cholera or travel diarrhea in a patient in need thereof by an effective amount of a compound of the formula wherein the substrates are defined in the specification or its non-toxic, pharmaceutically acceptable salts.

Abstract: The present invention relates to a method of treating hyperlipidemia and to reducing triacylglycerols, glycerol and cholesterol in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective somatostatin agonist to said patient. A pharmaceutical composition comprises said agonist and such product is used in the preparation of the composition for use in treating hyperlipidemia or reducing triacylglycerols, glycerol and cholesterol in a patient's body.

Abstract: A family of tetrahydroimidazo[1,2a]pyrazine based compounds capable of inhibiting the activity of farnesyl transferase and treating tumors and restenosis having the following structure: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in the specification.

Abstract: Compounds of the formula wherein R1 is alkyl and R2 is alkenyl, alkynyl, allenyl or cyanoalkyl, n is 0 or 1, k is an integer from 1 to 3, X is —(CH2)m— and m is 0 or 1; and pharmaceutical salts thereof useful for inhibiting NO synthases and/or monoamine oxydases.

Abstract: The invention concerns the use of pyrido-thieno-triazolo-diazepins for preparing a medicine for treating pathological conditions or diseases involving one of the growth hormone release inhibiting factor receptors. The invention also concerns novel pyrido-thieno-triazolo-diazepins and therapeutic compositions containing them.

Abstract: The invention relates to cross-linked copolymers based on non cross-linked polycarboxylic copolymers, said non cross-linked copolymers containing at least one polysaccharide. The invention also relates to a process for the preparation of these copolymers and their use in particular as a support in pharmaceutical compositions.

Abstract: The invention relates in particular to the compounds of general formula in which R1, R2, R3, R4, R5, R6 represent various radicals; their use as medicaments and pharmaceutical compositions containing them. These compounds are particularly useful for the treatment of cancer.

Abstract: The present invention pertains to biodegradable polymers comprising a non-polymerizable lactone, biodegradable compositions comprising the polymer and a therapeutic agent the use of the compositions for the sustained release of therapeutic agents, wherein the therapeutic agent is reversibly immobilized on the polymer matrix using ionic complexation between the latent carboxylic groups present on the lactone bearing polymer matrix and a cationic group on the therapeutic agent.

Abstract: The invention relates to a pre-filled injection device for injecting a liquid or semisolid composition into a subject, said injection device comprising: a housing (1) containing at its distal end the liquid or semisolid composition (2), a plunger (3) arranged to slide within the housing (1) to which is affixed a plunger stick (7) extending longitudinally from the plunger to the outside of the housing (1), a hollow needle (4) affixed to the distal end of the housing (1), said needle (4) connecting the interior part of the housing (1) with the outside where it extends longitudinally, and an airtight needle shield (5) which protects said needle (4), characterized in that said device further comprises a cap (6) designed to fit around the housing's proximal end and to fully cover said plunger stick (7), said cap (6) both preventing its accidental pushing or breakage before use and being adapted to receive the injection device once the injection into the subject has been carried out.

Abstract: Compounds of the formulae wherein the substituents are as defined in the specification useful for inhibiting NO synthase and regenerate antioxidants.

Abstract: The present invention is directed to peptide analogues of fragment of parathyroid hormone (PTH) or parathyroid hormone-related protein (PTHrP), a method of using said analogues alone or in combination with a bisphosphonate or calcitonin to treat osteoporosis and pharmaceutical compositions comprising said analogues alone or in combination with a bisphosphonate or calcitonin.

Abstract: A novel class of analogs which exhibit both high affinity and selectivity for Neuromedin B and Somatostann receptors are claimed. One example is Nal-Tyr-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH2.

Abstract: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues.